Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 9/20 | 0.46 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.45 |
| ▸ | F10 | P00742 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14700132 | 0.93 | ALDH1A1 (0.59) | ALDH1A1CYP3A4MAPK1SMN1; SMN2MEN1 | |
| SCHEMBL14700152 | 0.93 | ALDH1A1 (0.59) | ALDH1A1CYP3A4MAPK1SMN1; SMN2MEN1 | |
| SCHEMBL14700131 | 0.93 | ALDH1A1 (0.59) | ALDH1A1CYP3A4MAPK1SMN1; SMN2MEN1 | |
| SCHEMBL14701477 | 0.93 | ALDH1A1 (0.61) | ALDH1A1CYP3A4MAPK1SMN1; SMN2MEN1 | |
| SCHEMBL13508825 | 0.91 | ALDH1A1 (0.52) | ALDH1A1CYP3A4MAPK1SMN1; SMN2MEN1 | |
| SCHEMBL14700145 | 0.90 | ALDH1A1 (0.56) | ALDH1A1CYP3A4MAPK1SMN1; SMN2GABRA1 | |
| SCHEMBL14701476 | 0.89 | ABCB1 (0.50) | ALDH1A1CYP3A4MAPK1SMN1; SMN2MEN1 | |
| SCHEMBL16160532 | 0.87 | ALDH1A1 (0.49) | ALDH1A1CYP3A4MAPK1SMN1; SMN2MEN1 | |
| SCHEMBL15918823 | 0.87 | CYP3A4 (0.45) | ALDH1A1CYP3A4MAPK1SMN1; SMN2MEN1 | |
| SCHEMBL17359643 | 0.87 | CYP3A4 (0.45) | ALDH1A1CYP3A4MAPK1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187448-B2 | Flavonoid compounds | CARDERO THERAPEUTICS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140256741-A1 | FLAVONOID COMPOUNDS | CARDERO THERAPEUTICS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2013022846-A2 | FLAVONOID COMPOUNDS | CARDERO THERAPEUTICS, INC. (US) | 2013-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256741-A1 | FLAVONOID COMPOUNDS | FIS1, TFAM, MFN2 | ALDH1A1 1984/4885CYP3A4 3740/4885MAPK1 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.